Community Bank of Raymore Sells 5,633 Shares of Johnson & Johnson (NYSE:JNJ)

Community Bank of Raymore lessened its stake in Johnson & Johnson (NYSE:JNJ) by 64.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,082 shares of the company’s stock after selling 5,633 shares during the period. Community Bank of Raymore’s holdings in Johnson & Johnson were worth $450,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Christopher J. Hasenberg Inc purchased a new stake in Johnson & Johnson in the first quarter valued at about $31,000. Keener Financial Planning LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $40,000. WFA Asset Management Corp grew its holdings in shares of Johnson & Johnson by 61.4% during the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $44,000. Finally, Disciplined Equity Management Inc. purchased a new position in Johnson & Johnson in the 4th quarter worth $45,000. 69.55% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on JNJ. TD Cowen reduced their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. TD Securities decreased their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 8th. Morgan Stanley boosted their target price on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research report on Thursday, July 18th. Finally, The Goldman Sachs Group reduced their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $173.21.

Johnson & Johnson Price Performance

Shares of NYSE JNJ traded up $0.14 during midday trading on Wednesday, hitting $158.53. The stock had a trading volume of 1,917,028 shares, compared to its average volume of 7,335,667. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The stock has a 50 day simple moving average of $151.63 and a 200-day simple moving average of $153.06. The company has a market capitalization of $381.53 billion, a PE ratio of 9.89, a P/E/G ratio of 2.63 and a beta of 0.52. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.39.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter in the prior year, the company earned $2.80 EPS. Johnson & Johnson’s revenue was up 4.3% compared to the same quarter last year. On average, sell-side analysts expect that Johnson & Johnson will post 10.07 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.13%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.